Business
European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment
Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European
About this update from Enlivex Ltd.
[{"type":"text","content":"Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering ALLOCETRATM, the company’s immunotherapy product. This new patent adds intellectual property protection, including methods, uses and pharmaceutical compositions in the EU.\n ALLOCETRA™ is a novel immunotherapy based on a unique mechanism of action that targets life threatening diseases that are defined as “unmet medical needs” such as preventing or treating complications associated with bone marrow transplants (“BMT”) and/or hematopoietic stem cell transplants (“HSCT); organ dysfunction and acute multiple organ failure associated with sepsis and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing. ABOUT ENLIVEX Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visitwww.enlivex.com. Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of ALLOCETRATM programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the ind...